Introduction {#tca12609-sec-0005}
============

*EGFR, HER2, HER3,* and *HER4* are members of the ErbB receptor family.[1](#tca12609-bib-0001){ref-type="ref"}, [2](#tca12609-bib-0002){ref-type="ref"}, [3](#tca12609-bib-0003){ref-type="ref"}, [4](#tca12609-bib-0004){ref-type="ref"}, [5](#tca12609-bib-0005){ref-type="ref"}, [6](#tca12609-bib-0006){ref-type="ref"} These receptors form homodimer or heterodimer and activate downstream signaling that induces cell growth, differentiation, and carcinogenesis.[5](#tca12609-bib-0005){ref-type="ref"} EGF, transforming growth factor, amphiregulin, heparin‐binding EGF‐like growth factor, betacellulin, and epigen are ligands for *EGFR*; epiregulin is a ligand for both *EGFR* and *HER4*; heregulin (neuregulin 1 and neuregulin 2) is a ligand for *HER3* and *HER4*; and *HER2* has no ligand.[7](#tca12609-bib-0007){ref-type="ref"} These receptors play important roles in survival, proliferation, angiogenesis, and metastasis in many kinds of cancers.[7](#tca12609-bib-0007){ref-type="ref"}, [8](#tca12609-bib-0008){ref-type="ref"} In 2004, an activating *EGFR* mutation was reported to render lung cancer cells sensitive to gefitinib, an EGFR‐tyrosine kinase inhibitor (TKI).[9](#tca12609-bib-0009){ref-type="ref"}, [10](#tca12609-bib-0010){ref-type="ref"} The common activating mutations of *EGFR* are exon 19 deletion and exon 21 point mutation (L858R). Since the discovery that an activating *EGFR* mutation may render cancer cells sensitive to EGFR‐TKIs, many studies on mutations in lung cancer have been conducted and have yielded diverse results. For instance, the activating mutant *EGFR* with exon 19 deletion induces prolonged downstream signaling and enables transformation in vitro,[11](#tca12609-bib-0011){ref-type="ref"}, [12](#tca12609-bib-0012){ref-type="ref"} whereas both exon 19 deletion and L858R induce lepidic cell growth and form bronchoalveolar carcinoma that is sensitive to erlotinib, an EGFR‐TKI.[13](#tca12609-bib-0013){ref-type="ref"}, [14](#tca12609-bib-0014){ref-type="ref"} In lung cancers with activating *EGFR* mutations, mutant *EGFR* can cooperate with either *HER2* or *HER3* and activate downstream signaling, such as anti‐apoptotic signaling.[15](#tca12609-bib-0015){ref-type="ref"} Yatabe *et al*. reported that *EGFR* mutations are implicated in the development of terminal respiratory unit types of lung adenocarcinoma, and that amplification of mutant *EGFR* may be correlated to tumor progression from in situ lung adenocarcinoma to invasive adenocarcinoma.[16](#tca12609-bib-0016){ref-type="ref"}

To evaluate if HER2 or HER3 expression is implicated in lung adenocarcinoma progression, we focused on surgically resected stage 0 or IA1 lepidic predominant lung adenocarcinomas with or without *EGFR* mutations that exhibited ground glass nodules (GGNs) on chest computed tomography (CT). In this study, stage 0 or IA1 lung carcinoma were defined according to the International Association for the Study of Lung Cancer (IASLC) 8th Edition Tumor Node Metastasis (TNM) Classification of Lung Cancer.[17](#tca12609-bib-0017){ref-type="ref"} Stage 0 (Tis) adenocarcinoma refers to carcinoma in situ; stage IA1 lung adenocarcinoma includes minimally invasive (T1mi) adenocarcinoma exhibiting \< 3 cm of a predominately lepidic pattern with \< 5 mm invasion in any one focus, and T1a invasive adenocarcinoma, defined as a tumor with no more than 1 cm at the greatest dimension and unable to be classified as Tis or T1mi. These stages have neither lymph node nor distant metastasis. This type of lung adenocarcinoma reportedly harbors *EGFR* mutations at frequency of 61%.[18](#tca12609-bib-0018){ref-type="ref"} We compared *EGFR* mutations and HER2 and HER3 expression between stage 0 in situ lung adenocarcinoma and stage IA1 lung adenocarcinoma including minimally invasive and invasive adenocarcinoma.

Methods {#tca12609-sec-0006}
=======

Patient population and characteristics {#tca12609-sec-0007}
--------------------------------------

Records of patients with lung adenocarcinoma exhibiting GGN on chest CT and a lepidic histologic pattern that was surgically resected and classified as stage IA with T1N0M0 in 2009 were retrospectively evaluated. All patients signed written informed consent before participating in this study. The Medical Ethics Committee of Osaka International Cancer Institute (previously named the Medical Ethics Committee of Osaka Medical Center for Cancer and Cardiovascular Diseases until March 2017) approved the study, which was performed in accordance with the Helsinki Declaration. Adenocarcinoma reclassified into stage 0 (Tis) in situ adenocarcinoma or IA1 including minimally invasive (T1mi) and invasive adenocarcinoma (T1a) according to the IASLC 8th edition of the TNM Classification of Lung Cancer was used in this study.[17](#tca12609-bib-0017){ref-type="ref"} Gender, age, smoking history (Brinkmann's index), and the greatest dimension of predominately lepidic pattern measured as tumor size were evaluated. Additionally, the five‐year overall survival (OS) data for stage 0 and IA1 was calculated.

Analysis of *EGFR* mutation {#tca12609-sec-0008}
---------------------------

*EGFR* mutation was evaluated at LSI Medience Corporation using a peptide nucleic acid‐locked nucleic acid PCR clamp method.[19](#tca12609-bib-0019){ref-type="ref"} HER2 and HER3 expression was evaluated via immunohistochemistry at SRL Co. Ltd.

Immunohistochemistry {#tca12609-sec-0009}
--------------------

Immunohistochemistry was performed using the automated staining system, Ventana NX20 (Roche Diagnostics K.K., Tokyo, Japan) at SRL Co. Ltd. Rabbit polyclonal anti‐HER2 (Dako Denmark A/S, Glostrup, Denmark) and rabbit polyclonal anti‐HER3 (Santa Cruz Biotechnology, Inc., Dallas, TX, USA) antibodies were used. These antibodies were detected using an iVIEW DAB Detection Kit (Roche Diagnostics K.K.). Immunohistochemistry samples without anti‐HER2 or anti‐HER3 antibodies were used as negative controls. Protein expression was evaluated using light microscopy with low (×100), intermediate (×200), and high (×400) magnifications.

Positive expression was defined as strong expression of the examined protein in \> 30% of lung cancer cells compared to adjacent lung epithelial cells. Expression was defined as 1+, 2+ and 3+ in cases of weak and membrane staining, complete but moderate membrane staining, and strong and complete staining, respectively.

Statistical analysis {#tca12609-sec-0010}
====================

Statistical analysis was performed using EZR.[20](#tca12609-bib-0020){ref-type="ref"} Baseline patient characteristics were compared using Fisher's exact test for categorical variables (e.g. a ratio of men to women) and Mann--Whitney *U* test for continuous variables (e.g. age, Brinkman index, and tumor diameter). The frequency of *EGFR* mutations and HER2 and HER3 expression between adenocarcinoma in situ (stage 0) and others, including minimally invasive and invasive adenocarcinomas (stage IA1), were compared using Fisher's exact test. The intensity of HER2 or HER3 expression between the two groups was compared using Mann--Whitney *U* test. To evaluate the impact of the intensity of HER3 expression on progression from stage 0 to IA1, subgroup analysis was performed between subgroups with or without *EGFR* mutations using a Mann--Whitney *U* test.

Results {#tca12609-sec-0011}
=======

Patient characteristics {#tca12609-sec-0012}
-----------------------

The clinical and histopathological data are summarized in Table [1](#tca12609-tbl-0001){ref-type="table-wrap"}. A total of 36 cases of stage IA lung adenocarcinoma were reclassified into 10 cases of stage 0 in situ adenocarcinoma (Tis) and 26 cases of stage IA1 adenocarcinoma, including 15 cases of minimally invasive carcinoma (T1mi) and 11 cases of invasive carcinoma (T1a). None of the patients received EGFR‐TKIs before surgery. Five men and five women had stage 0 disease, whereas 10 men and 16 women had stage IA1. The median ages in stage 0 and IA1 groups were 62 and 68 years, respectively. There was no statistically significant difference in the Brinkman index in these groups. The mean diameter of adenocarcinoma in situ was 15.4 ± 7.1 mm (mean ± standard deviation), whereas that of minimally invasive and invasive adenocarcinoma was 20.7 ± 5.7 mm (mean ± standard deviation). Therefore, primary lesions in lung adenocarcinoma in situ with pure GGN (stage 0) have a smaller diameter than the invasive type (stage IA1).

###### 

Patient characteristics

  Characteristic                              Reclassified stage   Statistical analysis  
  ------------------------------------------ -------------------- ---------------------- ---------------------
  Number of cases                                     10                    26           
  Gender                                                                                 
  Female                                              5                     15           
  Male                                                5                     11             NS (*P* = 0.709)
  Median age (range)                            62.5 (20--66)         65.5 (20--83)        NS (*P* = 0.229)
  Smoking history (median Brinkmann index)       120 (0--720)          53(0--2000)         NS (*P* = 0.769)
  Mean tumor size (±SD)                         15.4 ± 7.1 mm         20.7 ± 5.7 mm       *P* \< 0.05 (0.001)
  Five‐year survival rate                            100%                 95.5%          

NS, not significant; SD, standard deviation.

One patient with stage IA1 died 11 months after surgical resection as a result of another (secondary) pleomorphic lung cancer. Postoperative five‐year follow‐up for four patients with stage IA1 was not obtained. No postoperative recurrence has been observed after five years of follow‐up. The five‐year OS rate was 100% for stage 0 and 95.5% for stage IA1 (Table [1](#tca12609-tbl-0001){ref-type="table-wrap"}).

*EGFR* mutation and HER2 and HER3 expression in stage 0--IA1 lung adenocarcinoma {#tca12609-sec-0013}
--------------------------------------------------------------------------------

*EGFR* mutation status was examined in the patient cohort. As shown in Table [2](#tca12609-tbl-0002){ref-type="table-wrap"}, PCR was successful for 35 patients and unsuccessful in one patient. *EGFR* mutations were detected in 16 (48.6%) of the 35 patients. Five of these cases had exon 19 deletions, and 11 had L858R. Nineteen cases lacked *EGFR* mutation. The frequency of *EGFR* mutation between adenocarcinoma in situ and invasive adenocarcinoma was not significant (40.0% and 48.0%, respectively).

###### 

EGFR mutation and HER2 and HER3 expression in stage 0--IA1 lung adenocarcinoma

                      Reclassified stage Statistical analysis       
  ------------------ ----------------------------------------- ---- --------------------------------
  *EGFR* mutation                                                   
  Unsuccessful                           0                      1   
  Negative                               6                      13  
  Positive                               4                      12  NS (*P* = 0.723)
  Exon 19 deletion                       1                      4   
  L858R                                  3                      8   
  HER2                               Negative                   9   19
  Positive                                                      7   Frequency: NS (*P* = 0.397)
  1+                                     1                      5   
  2+                                     0                      2   Intensity: NS (*P* = 0.769)
  3                                      0                      0   
  HER3                               Negative                   4   1
  Positive                               6                      25  Frequency: *P* \< 0.05 (0.015)
  1+                                     5                      19  Intensity: *P* \< 0.05 (0.01)
  2+                                     1                      5   
  3+                                     0                      1   

NS, not significant; SD, standard deviation.

Figure [1](#tca12609-fig-0001){ref-type="fig"} shows images obtained from immunohistochemistry of negative and 2+ expression of HER2 and HER3, respectively. Immunohistochemistry results are summarized in Table [2](#tca12609-tbl-0002){ref-type="table-wrap"}. HER2 was detectable in 8 out of 36 cases. The frequency of HER2 expression was not significantly different between stage 0 and stage IA1, and its intensity in stage IA1 was not higher than in stage 0 adenocarcinoma. When compared with adjacent lung epithelium cells, HER3 expression was positive in 86.8% of lung cancers tested. The frequency of HER3 expression was 60.0% for stage 0 adenocarcinoma in situ and statistically significantly more frequent (96.1%) in advanced stage (stage IA1). In addition, the intensity of HER3 expression in stage IA1 was greater than in adenocarcinoma in situ (stage 0).

![Representative immunohistochemistry images of lung adenocarcinoma (left) versus negative control (immunohistochemistry without anti‐HER2; right). (**a**) HER2(−), (**b**) HER2(2+), (**c**) HER3(−), and (**d**) HER3 (2+). All images were obtained at 200× magnification.](TCA-9-466-g001){#tca12609-fig-0001}

Meanwhile, there was no statistically significant difference in *EGFR* status, HER2 expression and intensity, or baseline patient characteristics other than tumor diameter between adenocarcinoma in situ and stage IA1 cancer. We evaluated whether the intensity of HER3 expression might be enhanced in advanced lung adenocarcinoma with active *EGFR* mutations. As shown in Table [3](#tca12609-tbl-0003){ref-type="table-wrap"}, subgroup analysis revealed that the intensity of HER3 expression was only enhanced in the group with advanced cancer without any *EGFR* mutations.

###### 

Subgroup analysis of the correlation between HER3 expression level and stage with or without *EGFR* mutation

  Mutation/Expression       Reclassified stage   Statistical analysis                                 
  ------------------------ -------------------- ---------------------- ---- ---- ----- ---- ---- ---- -------------------------------
  HER3 expression                  ---                    1+            2+   3+   ---   1+   2+   3+  
  EGFR mutation negative            3                     3             0    0     1    8    3    1    Intensity: *P* \< 0.05 (0.03)
  EGFR mutation positive            1                     2             1    0     0    10   2    0      Intensity: NS *P* = 0.689

NS, not significant; SD, standard deviation.

Discussion {#tca12609-sec-0014}
==========

*EGFR* with activating mutations, including exon 19 deletion and L858R mutation, is a driver oncogene that induces lepidic cell growth and forms bronchoalveolar carcinoma in vivo.[13](#tca12609-bib-0013){ref-type="ref"}, [14](#tca12609-bib-0014){ref-type="ref"} Although lung cancers with *EGFR* mutation are initially sensitive to EGFR‐TKIs, they show acquired resistance.[9](#tca12609-bib-0009){ref-type="ref"}, [10](#tca12609-bib-0010){ref-type="ref"} The most frequent mechanism of acquired resistance is T790M point mutation of *EGFR.* [21](#tca12609-bib-0021){ref-type="ref"} In some lung cancers with *EGFR* mutation, HER2 amplification[22](#tca12609-bib-0022){ref-type="ref"} causes the resistance, and heregulin, a ligand of HER3, is increased during EGFR‐TKI treatment,[23](#tca12609-bib-0023){ref-type="ref"} suggesting that HER2 or HER3 may be implicated in the resistance of lung cancers to EGFR‐TKI treatment. Therefore, HER3 may be a therapeutic target against lung cancer exhibiting EGFR‐TKI resistance.[24](#tca12609-bib-0024){ref-type="ref"} The HER3‐targeted antibody, patritumab, combined with erlotinib has been evaluated in non‐small cell lung cancer harboring EGFR‐mutations.[25](#tca12609-bib-0025){ref-type="ref"} In addition, the tolerance and efficacy of HER3 target therapy against various kinds of cancers without *EGFR* mutations, such as breast cancer overexpressing HER2 and head and neck cancer, have also been examined.[26](#tca12609-bib-0026){ref-type="ref"}, [27](#tca12609-bib-0027){ref-type="ref"} These three studies indicate encouraging efficacy of combination therapies with HER3 target therapies.

On the other hand, HER3 is associated with poor prognosis in gastric cancer.[28](#tca12609-bib-0028){ref-type="ref"} As HER3 can homodimerize or heterodimerize with ErbB family receptors, it also might be implicated in the progression or maintenance of the malignant phenotype of non‐small cell lung cancer without EGFR mutations. However, little is known about how HER2 and HER3 impact progression from stage 0 to IA1 of lung cancer without *EGFR* mutations and lung cancer harboring *EGFR* mutations when they are not treated with EGFR‐TKIs.

This study focused on an analysis of the implications of HER2 or HER3 in local progression from carcinoma in situ to invasive solid adenocarcinoma. The five‐year OS rate was 100% for stage 0 and 95.5% for stage IA1. Therefore, this study might not be suitable as an analysis of the relationship between recurrence and HER2 or HER3 because the mechanism of lung adenocarcinoma in situ progression may have little influence on the postoperative outcome.

In this study, we observed that the presence or absence of *EGFR* mutation is not implicated in cancer progression during the early stage, which is consistent with previous data suggesting that *amplification* rather than *EGFR* mutation is associated with lung adenocarcinoma progression.[16](#tca12609-bib-0016){ref-type="ref"} This result is consistent with reports implicating *EGFR* in carcinogenesis.[13](#tca12609-bib-0013){ref-type="ref"}, [14](#tca12609-bib-0014){ref-type="ref"} We observed that the frequency and intensity of HER3 protein expression is higher in stage IA1 than in stage 0 lung cancer. In addition, the intensity of HER3 expression is associated with the progression of lung adenocarcinoma without *EGFR* mutations. On the other hand, no association was observed between the progression and HER2 by our analysis. Therefore, increased HER3 expression might be implicated in the progression of lung cancer without *EGFR* mutations. On the other hand, we have previously reported that the neuregulin 1/HER3 pathway activates the AKT signal and induces spheroid culture of primary lung cancer cells, including those harboring wild type *EGFR*,[29](#tca12609-bib-0029){ref-type="ref"} suggesting that HER3 activation may convey a growth advantage even in lung cancer without *EGFR* mutations.

Further studies are needed to validate whether increased HER3 expression is responsible for cancer progression. Although no correlation between HER3 expression and progression of lung adenocarcinoma harboring *EGFR* mutations was found, we cannot conclude that HER3 is not implicated in the progression from stage 0 to IA as our analysis only included a small number of cases, which may affect the result with regard to lung cancer with *EGFR* mutations.

Collectively, our results indicate that HER3 is not only a therapeutic target for EGFR‐TKI resistant lung cancer harboring *EGFR* mutations, but may also prevent advanced stage lung adenocarcinoma without *EGFR* mutations from further progression.
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